Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease

Midori Hasegawa, Junichi Ishii, Fumihiko Kitagawa, Hiroshi Takahashi, Kazuhiro Sugiyama, Masashi Tada, Kyoko Kanayama, Kazuo Takahashi, Hiroki Hayashi, Shigehisa Koide, Shigeru Nakai, Yukio Ozaki, Yukio Yuzawa

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. Our aim was to assess plasma neutrophil gelatinase-associated lipocalin (NGAL) as a predictor of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and no history of CV events. Methods. This was a prospective observational cohort study of 252 patients with predialysis CKD. CV events were defined as CV death, acute coronary syndrome, and hospitalization for worsening heart failure, stroke, and aortic dissection. Results. During a median follow-up period of 63 months, 36 CV events occurred. On Cox stepwise multivariate analysis, plasma NGAL and B-type natriuretic peptide (BNP) were significant predictors of CV events. Kaplan-Meier incidence rates of CV event-free survival at 5 years were 96.6%, 92.9%, 85.9%, and 61.3%, respectively, among quartiles of plasma NGAL (P < 0. 0001). The C-index for the receiver-operating characteristic curves for CV events was greater when plasma NGAL was added to an established risk model (0.801, 95% CI 0.717-0.885), compared to the model without plasma NGAL (0.746, 95% CI 0.653-0.840, P = 0.0 21). Conclusion. Elevated plasma NGAL could predict future CV events in CKD patients with no history of CV events and add incremental value to the established risk model.

Original languageEnglish
Article number8761475
JournalBioMed Research International
Volume2016
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Lipocalins
Gelatinases
Chronic Renal Insufficiency
Plasmas
Dissection
Brain Natriuretic Peptide
Acute Coronary Syndrome
ROC Curve
Disease-Free Survival
Observational Studies
Lipocalin-2
Hospitalization
Cohort Studies
Multivariate Analysis
Heart Failure
Stroke
Incidence

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Hasegawa, Midori ; Ishii, Junichi ; Kitagawa, Fumihiko ; Takahashi, Hiroshi ; Sugiyama, Kazuhiro ; Tada, Masashi ; Kanayama, Kyoko ; Takahashi, Kazuo ; Hayashi, Hiroki ; Koide, Shigehisa ; Nakai, Shigeru ; Ozaki, Yukio ; Yuzawa, Yukio. / Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease. In: BioMed Research International. 2016 ; Vol. 2016.
@article{63358e4d23804900a458ca8f2060144b,
title = "Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease",
abstract = "Background. Our aim was to assess plasma neutrophil gelatinase-associated lipocalin (NGAL) as a predictor of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and no history of CV events. Methods. This was a prospective observational cohort study of 252 patients with predialysis CKD. CV events were defined as CV death, acute coronary syndrome, and hospitalization for worsening heart failure, stroke, and aortic dissection. Results. During a median follow-up period of 63 months, 36 CV events occurred. On Cox stepwise multivariate analysis, plasma NGAL and B-type natriuretic peptide (BNP) were significant predictors of CV events. Kaplan-Meier incidence rates of CV event-free survival at 5 years were 96.6{\%}, 92.9{\%}, 85.9{\%}, and 61.3{\%}, respectively, among quartiles of plasma NGAL (P < 0. 0001). The C-index for the receiver-operating characteristic curves for CV events was greater when plasma NGAL was added to an established risk model (0.801, 95{\%} CI 0.717-0.885), compared to the model without plasma NGAL (0.746, 95{\%} CI 0.653-0.840, P = 0.0 21). Conclusion. Elevated plasma NGAL could predict future CV events in CKD patients with no history of CV events and add incremental value to the established risk model.",
author = "Midori Hasegawa and Junichi Ishii and Fumihiko Kitagawa and Hiroshi Takahashi and Kazuhiro Sugiyama and Masashi Tada and Kyoko Kanayama and Kazuo Takahashi and Hiroki Hayashi and Shigehisa Koide and Shigeru Nakai and Yukio Ozaki and Yukio Yuzawa",
year = "2016",
month = "1",
day = "1",
doi = "10.1155/2016/8761475",
language = "English",
volume = "2016",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease. / Hasegawa, Midori; Ishii, Junichi; Kitagawa, Fumihiko; Takahashi, Hiroshi; Sugiyama, Kazuhiro; Tada, Masashi; Kanayama, Kyoko; Takahashi, Kazuo; Hayashi, Hiroki; Koide, Shigehisa; Nakai, Shigeru; Ozaki, Yukio; Yuzawa, Yukio.

In: BioMed Research International, Vol. 2016, 8761475, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Plasma Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Cardiovascular Events in Patients with Chronic Kidney Disease

AU - Hasegawa, Midori

AU - Ishii, Junichi

AU - Kitagawa, Fumihiko

AU - Takahashi, Hiroshi

AU - Sugiyama, Kazuhiro

AU - Tada, Masashi

AU - Kanayama, Kyoko

AU - Takahashi, Kazuo

AU - Hayashi, Hiroki

AU - Koide, Shigehisa

AU - Nakai, Shigeru

AU - Ozaki, Yukio

AU - Yuzawa, Yukio

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background. Our aim was to assess plasma neutrophil gelatinase-associated lipocalin (NGAL) as a predictor of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and no history of CV events. Methods. This was a prospective observational cohort study of 252 patients with predialysis CKD. CV events were defined as CV death, acute coronary syndrome, and hospitalization for worsening heart failure, stroke, and aortic dissection. Results. During a median follow-up period of 63 months, 36 CV events occurred. On Cox stepwise multivariate analysis, plasma NGAL and B-type natriuretic peptide (BNP) were significant predictors of CV events. Kaplan-Meier incidence rates of CV event-free survival at 5 years were 96.6%, 92.9%, 85.9%, and 61.3%, respectively, among quartiles of plasma NGAL (P < 0. 0001). The C-index for the receiver-operating characteristic curves for CV events was greater when plasma NGAL was added to an established risk model (0.801, 95% CI 0.717-0.885), compared to the model without plasma NGAL (0.746, 95% CI 0.653-0.840, P = 0.0 21). Conclusion. Elevated plasma NGAL could predict future CV events in CKD patients with no history of CV events and add incremental value to the established risk model.

AB - Background. Our aim was to assess plasma neutrophil gelatinase-associated lipocalin (NGAL) as a predictor of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and no history of CV events. Methods. This was a prospective observational cohort study of 252 patients with predialysis CKD. CV events were defined as CV death, acute coronary syndrome, and hospitalization for worsening heart failure, stroke, and aortic dissection. Results. During a median follow-up period of 63 months, 36 CV events occurred. On Cox stepwise multivariate analysis, plasma NGAL and B-type natriuretic peptide (BNP) were significant predictors of CV events. Kaplan-Meier incidence rates of CV event-free survival at 5 years were 96.6%, 92.9%, 85.9%, and 61.3%, respectively, among quartiles of plasma NGAL (P < 0. 0001). The C-index for the receiver-operating characteristic curves for CV events was greater when plasma NGAL was added to an established risk model (0.801, 95% CI 0.717-0.885), compared to the model without plasma NGAL (0.746, 95% CI 0.653-0.840, P = 0.0 21). Conclusion. Elevated plasma NGAL could predict future CV events in CKD patients with no history of CV events and add incremental value to the established risk model.

UR - http://www.scopus.com/inward/record.url?scp=84962921747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962921747&partnerID=8YFLogxK

U2 - 10.1155/2016/8761475

DO - 10.1155/2016/8761475

M3 - Article

C2 - 27051671

AN - SCOPUS:84962921747

VL - 2016

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 8761475

ER -